These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 29069819)

  • 1. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus.
    Wang SL; Dong WB; Dong XL; Zhu WM; Wang FF; Han F; Yan X
    Oncotarget; 2017 Sep; 8(42):72700-72713. PubMed ID: 29069819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of different antidiabetic drugs based on metformin in the treatment of type 2 diabetes mellitus: A network meta-analysis involving eight eligible randomized-controlled trials.
    Peng Y; Chen SH; Liu XN; Sun QY
    J Cell Physiol; 2019 Mar; 234(3):2795-2806. PubMed ID: 30145806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Single- or Double-Drug Antidiabetic Regimens in the Treatment of Type 2 Diabetes Mellitus: A Network Meta-Analysis.
    Yang XL; Duo-Ji MM; Long ZW
    J Cell Biochem; 2017 Dec; 118(12):4536-4547. PubMed ID: 28471499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term efficacy and safety of repaglinide versus glimepiride as augmentation of metformin in treating patients with type 2 diabetes mellitus.
    Xie J; Li N; Jiang X; Chai L; Chen JJ; Deng W
    Diabetes Metab Syndr Obes; 2019; 12():519-526. PubMed ID: 31114280
    [No Abstract]   [Full Text] [Related]  

  • 5. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US.
    Lee WC; Conner C; Hammer M
    Curr Med Res Opin; 2011 May; 27(5):897-906. PubMed ID: 21348806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy of glimepiride and metformin in monotherapy of type 2 diabetes mellitus: meta-analysis of randomized controlled trials.
    Zhu H; Zhu S; Zhang X; Guo Y; Shi Y; Chen Z; Leung SW
    Diabetol Metab Syndr; 2013 Nov; 5(1):70. PubMed ID: 24228743
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of liraglutide combined with metformin or acarbose on glucose control in type 2 diabetes mellitus and risk factors of gastrointestinal adverse reactions.
    Ren G; Ma X; Jiao P
    Am J Transl Res; 2022; 14(5):3207-3215. PubMed ID: 35702127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of effects of gliclazide, metformin and pioglitazone monotherapies on glycemic control and cardiovascular risk factors in patients with newly diagnosed uncontrolled type 2 diabetes mellitus.
    Erem C; Ozbas HM; Nuhoglu I; Deger O; Civan N; Ersoz HO
    Exp Clin Endocrinol Diabetes; 2014 May; 122(5):295-302. PubMed ID: 24710641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone, rosiglitazone, and rosiglitazone + metformin: new drugs. Glitazone + oral antidiabetic combination: inadequately evaluated.
    Prescrire Int; 2005 Aug; 14(78):133-9. PubMed ID: 16106595
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
    Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
    Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: meta-analysis of placebo-controlled trials.
    Monami M; Vitale V; Ambrosio ML; Bartoli N; Toffanello G; Ragghianti B; Monami F; Marchionni N; Mannucci E
    Adv Ther; 2012 Sep; 29(9):736-46. PubMed ID: 22923161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The short-term cost-effectiveness of once-daily liraglutide versus once-weekly exenatide for the treatment of type 2 diabetes mellitus in the United States.
    Wang B; Roth JA; Nguyen H; Felber E; Furnback W; Garrison LP
    PLoS One; 2015; 10(4):e0121915. PubMed ID: 25849542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.
    Pinelli NR; Cha R; Brown MB; Jaber LA
    Ann Pharmacother; 2008 Nov; 42(11):1541-51. PubMed ID: 18957626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rosiglitazone/metformin fixed-dose combination therapy and metformin monotherapy on serum vaspin, adiponectin and IL-6 levels in drug-naïve patients with type 2 diabetes.
    Kadoglou NP; Kapelouzou A; Tsanikidis H; Vitta I; Liapis CD; Sailer N
    Exp Clin Endocrinol Diabetes; 2011 Feb; 119(2):63-8. PubMed ID: 21031343
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome.
    Liu Z
    Pak J Med Sci; 2024; 40(1Part-I):26-30. PubMed ID: 38196473
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.